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Brief title: Allogeneic pPICs enhance repair of injured muscle 
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(Activation of vasculature-associated stem cells and muscle stem cells for the repair and 
maintenance of muscle tissue).  There are no relationships with industry. Structured Abstract: 
Objective: To assess whether delivery of allogeneic skeletal muscle-derived PW1pos/Pax7neg 
interstitial cells (PICs) enhance the regeneration of injured skeletal muscle in a porcine pre-
clinical model, with similarities to human muscle, in terms of anatomical size, tissue biology, 
and physiology. 
Background:  An accepted consensus has gained ground that cell therapy protocols exert their 
beneficial effect by a ‘paracrine’ mechanism of the transplanted cells through the activation of 
endogenous reparative processes. PICs can be reproducibly isolated from skeletal muscle, 
propagated over long-term culture, while maintaining a stable phenotype/genotype.  
Methods: We induced injury through a localized injection of cardiotoxin to Tibialis Anterior 
skeletal muscle of pigs. This was followed by intra-muscular delivery of 20x106 allogeneic 
GFPpos pPICs per pig or saline vehicle control.  BrdU was administered to track cell 
regeneration. Pigs were sacrificed 14 days post-injury. The secretome of transplanted pPICs was 
assessed using qRT-PCR arrays. 
Results: Allogeneic, GFPpos pPIC transplantation significantly accelerated and improved 
endogenous, GFP-negative skeletal muscle fiber (15±3% vs. 2±1%/total myofiber) and capillary 
(0.15±0.04 vs. 0.04±0.01/myofiber) regeneration, compared to saline vehicle control. Moreover, 
pPIC transplantation activated endogenous GFP-negative skeletal muscle progenitor cells 
(7.9±1.9% vs. 4.6±0.5%/total nuclei). pPICs exhibited a wide range expression profile of 
regenerative cytokines and paracrine factors, specifically IGF-1 and NRG-1. As would be 
expected, negligible donor GFPpos pPICs persisted within the host skeletal muscle at 14 days 
post-injury, suggesting allogeneic GFPpos pPICs were eliminated by the host immune system. 
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Conclusions: Allogeneic progenitor cell therapy stimulates endogenous repair and regeneration 
in a pre-clinical muscle model applicable to humans.  
 
Condensed Abstract: 
Skeletal muscle-derived PW1pos/Pax7neg interstitial cells (PICs) express and secrete a multitude 
of pro-regenerative growth factors and cytokines. Utilizing a porcine pre-clinical skeletal muscle 
injury model, delivery of allogeneic pPICs significantly improved and accelerated myofiber 
regeneration and neocapillarization, compared to saline vehicle control-treated muscles. 
Allogeneic pPICs did not contribute to new myofibers or capillaries and were eliminated by the 
host immune system. In conclusion, allogeneic pPIC transplantation stimulated the endogenous 
stem cell pool to bring about enhanced autologous skeletal muscle repair and regeneration. This 
allogeneic cell approach is considered a cost-effective, easy to apply and readily available 
regenerative therapeutic strategy. 
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Skeletal muscle is a dynamic, highly plastic tissue that is capable of undergoing repair and 
regeneration in healthy individuals (1).  However, this regenerative capacity can become 
impaired in muscle diseases, such as muscular dystrophy, and as a result of disuse and ageing (2, 
3).  This leads to decreased proliferation, delayed fusion and reduced differentiation of muscle 
progenitors, as well as a gradual replacement of muscle fibers by fat and fibrosis with poor 
vascularization (4, 5).  The mechanisms that underpin impaired skeletal muscle regeneration are 
still unclear however recent findings suggest that the microenvironment and/or systemic factors 
(6, 7) affect the response of various endogenous skeletal muscle progenitor cells to repair and 
regenerate after injury (8).  This has led us to focus upon therapeutic strategies that target 
resident muscle progenitors and stimulate endogenous repair mechanisms. 
 
Autologous stem cell approaches are attractive from a theoretical and biological standpoint, 
however for skeletal muscle where the muscle satellite cells cannot be effectively propagated to 
large numbers in vitro and like other tissue specific stem/progenitor cells, such as cardiac, are 
affected by age and disease, they are impractical. Moreover, administration of cells can induce 
therapeutic responses by indirect means, such as secretion of growth factors and interaction with 
endogenous repair processes, represented by the resident stem/progenitor cells (9, 10). This has 
been termed the paracrine effect. Therefore, there seems to be little advantage in the use of 
autologous cells because a similar, and perhaps enhanced, effect can be obtained by the 
administration of a cell type isolated from allogeneic sources, which could be made readily 
available at reduced costs (11). We have previously shown that intracoronary injection of 
allogeneic porcine cardiac stem cells (CSCs) after myocardial infarction (MI) activates the 
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endogenous, resident CSCs through a paracrine mechanism resulting in improved myocardial 
cell survival, function, remodeling and regeneration (12).   
Skeletal muscle satellite cells although capable of muscle fiber regeneration, have a limited 
migration capacity with an inability to cross the endothelial wall (13). Moreover, cultured 
satellite cells ex vivo have decreased stemness, proliferation, and myofiber differentiation, which 
has subsequently hampered their translation (14).  In recent years, skeletal muscle has been 
shown to harbor other stem/progenitor cells, such as the PW1pos/Pax7neg interstitial cells (PICs), 
which are bi-potent giving rise to new skeletal muscle fibers and vasculature-associated cell 
types in vitro and in vivo (15, 16). Unlike the satellite cells, we have shown that porcine PICs 
(pPICs) can be successfully isolated and propagated in vitro up to passage 40, while maintaining 
a stable phenotype/genotype (16). Therefore PICs represent an attractive and alternative cell 
source for regenerative therapies. 
 
The pig represents an excellent biological model for human biomedical pre-clinical research due 
to its anatomical, physiological, pathological and genomic similarities to humans (18).  In terms 
of porcine skeletal muscle biology considerable correlation between contractile, metabolic, and 
morphological features to human skeletal muscle exist (19-21).  Although small animal models 
are a valuable resource they do not always accurately reflect the clinical manifestation with many 
cell therapies that have been shown to be highly effective in small animal models (22, 23), 
yielding only modest therapeutic value in human clinical trials (24, 25). Combined with the three 
orders of magnitude difference in mass between the two species there is an obvious need to test 
cell therapies in more illustrative animal models. Developing a porcine pre-clinical model for 
skeletal muscle regeneration can provide a useful link between the widely used rodent models 
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and humans so that an improved prediction of efficacy of therapies can be achieved and 
successfully translated to patients. Moreover, unlike other organs, the skeletal muscle is an 
efficient regenerative tissue yielding adequate resident progenitor cells, which give rise to new 
myofibers and vasculature following injury. Altogether, this makes the porcine skeletal muscle 
an appropriate model system to test proof-of-concept regenerative therapeutic approaches, such 
as the allogeneic cell approach described here, for the first time. Allogeneic stem cell therapy is 
conceptually and practically different from any presently in clinical use and could be applied in 
the repair and regeneration of other tissues such as the heart. 
 
Here we tested the therapeutic reparative effect of delivering allogeneic porcine PW1pos/Pax7neg 
interstitial cells (pPICs) to the injured pig skeletal muscle.  We hypothesized that allogeneic 
pPICs transplanted following skeletal muscle injury would supply regenerative bioactive factors 
capable of activating the endogenous stem/progenitor cells, enhancing and accelerating the 
regeneration of damaged skeletal muscle tissue. It was also hypothesized that the allogeneic 
pPICs survive long enough in the allogeneic host to produce their paracrine effect activating the 
endogenous target cells before being eliminated by the host immune system. Therefore, the cells 













Study Design, Skeletal Muscle Injury and Intramuscular pPIC Administration  
Animals were immune-competent, 2-month-old (juvenile), female, large Dalland Landrace pigs 
(32±5kg).  All animal procedures were performed in accordance with the EU Directive 
guidelines and regulations for animal experimentation by appropriately qualified staff and 
approved by the institutional animal welfare and ethical review board DEC Utrecht, The 
Netherlands. Pigs were sedated with 4mg/kg thiopental sodium and anaesthesia maintained with 
midazolam (0.5mg/kg/hr) via an intravenous catheter placed in a peripheral ear vein before 
intubation. The animals were subsequently moved to the surgery room and secured to the 
surgical table with limb bindings.  The lower hind limb was shaved and disinfected using iodine 
prior to surgery.   
The first phase of the in vivo study utilized 6 pigs.  In order to assess two different injury models 
either an open freeze/crush (n=3) or cardiotoxin injury (n=3) of the tibialis anterior muscle were 
subsequently performed. Briefly, a 5cm longitudinal incision of the skin and underlying fascia 
was made along the anterior aspect of the distal limb.  The skin and fascia were retracted, the TA 
muscle located, non-absorbable prolene sutures (Ethicon) were used to mark the injury site (1cm 
x 1cm2) and the injury was induced. In the case of freeze/crush injury, the muscle was crushed 
with forceps (Fine Science Tools), pre-cooled in liquid nitrogen.  This procedure was repeated 
seven times for 5s each in direct continuity with the respective distal crush in the defined area. In 
the case of cardiotoxin injury induction, a 10µM cardiotoxin solution, Naja mossambica 
mossambica (Sigma), was filtered and brought to room temperature before injection.  The 
cardiotoxin was dispersed in a series of five intramuscular injections using a 25 gauge needle to 
deliver a total volume of 500µl to the pre-defined area.  The contralateral leg served as a sham-
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control and was treated identically however no injury was applied in the case of freeze/crush or 
PBS alone was injected in animals receiving the CTX injury. The injury area was identified 
through marking with sutures. After injury-induction the superficial skin was sutured, animals 
were allowed to recover and then sacrificed by anesthetic overdose at either 14 or 21 days post-
injury.  
In the second phase of the in vivo study 10 pigs were randomly assigned to receive either saline 
vehicle (PBS) or allogeneic GFPpos pPICs, 15 minutes post-CTX injury. GFPpos pPICs were 
propagated and cryostored between P3-P12.  Prior to transplantation GFPpos pPICs were pre-
mixed, brought into suspension, centrifuged, washed twice with PBS, and counted.  20x106 
GFPpos pPICs were resuspended in 500µl PBS and injected intramuscularly into the injured TA 
through a 25 gauge needle, n=5. Control animals were treated identically however 500µl PBS 
alone was injected, n=5.  Both treatments were distributed across five injection sites to the injury 
site. The contralateral control leg of each animal served as a sham CTRL and received no injury 
just PBS using the same protocol.  
In separate pigs local delivery of human recombinant IGF-1 (8μg) and HGF (2μg) (Peprotech) 
was achieved by diluting both growth factors in PBS in a total volume of 500μl before being 
dispersed in a series of five intramuscular injections using a 25 gauge needle to deliver a total 
volume of 500µl to the pre-defined injured area, n=5. In the case of UPy+IGF-1/HGF treatment, 
the UPy-hydrogelators were synthesized by SyMO-Chem BV, Eindhoven, The Netherlands, as 
described previously (26). To prepare the hydrogel, polymer solutions were dissolved at 10wt% 
in PBS by stirring at 70 °C for 1 hour and subsequently cooled to room temperature. To liquefy 
the polymer solution, the pH was increased to pH 8.5 by adding 2μL aliquots of a 0.1M NaOH 
stock solution. The hydrogel was then UV-sterilized for 1 hour and human recombinant IGF-1 
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(Peprotech) and HGF (Peprotech) were added prior to use, yielding a final concentration of 8μg 
and 2μg respectively. A total volume of 500μl UPy hydrogel+IGF-1/HGF were administered as 
per the method described above, n=5. 
In order to track newly formed cells post-injury we used the thymidine analogue, 5-bromo-2'-
deoxyuridine (BrdU).  In order to deliver BrdU to the animals over the course of the regeneration 
period we utilised an intravenous (IV) delivery system. This involved making a channel through 
the pig’s neck musculature and feeding an IV line through, which was subsequently connected to 
the jugular vein.  This enabled us to access a cannula situated on the dorsal aspect of the pig’s 
neck, which was directly linked to pig’s circulation system.  This method allowed daily 
administration of BrdU at a dose of 10mg/kg/day without the need to sedate the animals. 
Animals were sacrificed by anaesthetic overdose at 14 days post-injury. 
 
Cell culture  
Porcine PICs were isolated and maintained as previously described (15) in growth media; 
Dulbecco’s MEM/Ham’s F12 (DMEM/F12; Sigma) medium containing 10% embryonic stem 
cell qualified-fetal bovine serum (ESQ‐ FBS) (Invitrogen), leukemia inhibitory factor (LIF) 
(10ng/ml; Millipore), bFGF (10ng/ml; Peprotech), EGF (20ng/ml; Peprotech), insulin- 
transferrin-selenite (ITS; Invitrogen), 1% penicillin/streptomycin (Invitrogen), and 0.1% 
gentamicin (10 mg/ml; Invitrogen). Myogenic differentiation was induced by replacing growth 
media with DMEM/F12, 2% horse serum for either 24 hours or 5 days. Human myoblasts were 
isolated and maintained as previously described (16).  Human umbilical vein endothelial cells 
(HUVECs) (Lonza) were cultured in endothelial cell growth medium (EBM) supplemented with 




GFP transduction of pPICs 
 To generate GFP lentivirus HEK293T cells were cultured overnight in dishes pre-coated with 
0.1mg/ml collagen solution (Sigma) in DMEM, 10% FCS, 2% glutamax and 1% pen/strep until 
70% confluent. The following day, a mix of 6.5µg pCMV Δ8.9 packaging plasmid, 3.5µg VSV-
g envelope plasmid and 10µg GFP expression construct were diluted in 500µl OptiMEM-1 
without FCS or antibiotics.  A second mixture, containing 30µl Lipofectamine 2000 
(LifeTechnologies) in 500µl OptiMEM-1 without FCS or antibiotics, was added to the plasmid 
mix solution and incubated at room temperature for 20 min inverting the tube every 5 min. The 
plasmid/lipofectamine mixture was added dropwise to the HEK293 cells and incubated at 37 °C 
for 4h.  After 4h an equal volume of OptiMEM-1 with the addition of 10% FCS and 1% 
pen/strep was added.  The supernatant was collected 48h post-transfection and filtered with a 
0.45 mm filter.  The viral supernatant was subsequently concentrated using a lenti-X-
concentrator kit (Clontech) according to manufacturer’s specification and viral titre measured 
using GoStix (Clontech). The pseudovirus was subsequently used for transduction or stored at -
80°C. Target pPICs at passage 2 were transduced by adding 30µl/ml pseudovirus in DMEM, 
10% FCS containing 12µg/ml polybrene. After 24h media was changed to DMEM with the 
addition of serum and antibiotics. The infected target cells were further cultured and analyzed at 
24h post-transduction for GFP expression, using fluorescent microscopy and flow cytometry. 
Porcine PICs transduced with the GFP reporter gene were propagated for allogeneic 





Flow cytometry was performed as previously described (14) Immunophenotyping was performed 
using the following antibodies; PW1 (antibody kindly gifted by D. Sassoon), CD34 
(ThermoScientific), CD45 (AbD Serotec), Pax7 (DSHB). Isotype controls were used to define 
the specific gates and analysis was performed using a FACSCantoII with FACSDiva software 
(BD BioSciences).  
 
Tissue processing and Histology 
Whole tibialis anterior muscles were excised, washed in PBS, weighed and fixed in 10% 
formalin with gentle agitation for 4 days. Muscles were processed for paraffin embedding using 
a Leica TP1020 tissue processor as previously described (15). To measure myofiber diameter 
and identify fibrosis, muscle sections were stained with hematoxylin and Van Gieson (HVG), 
respectively, according to standard procedures (25). Cross sectional area (CSA) of connective 
tissue was determined from five fields of view at x20 magnification per muscle using ImageJ 
analysis. To determine the mean myofiber diameters, measurements were performed on 
transverse sections with 100 myofibers analyzed per section.   
 
Immunohistochemistry/immunocytochemistry 
To identify regenerating muscle fibers, muscle sections were stained with anti- human neonatal 
myosin heavy chain (nMHC) (DSHB). Sections were also stained with anti- laminin (Abcam) to 
identify the basal lamina of individual fibers and centralized nuclei identified through DAPI 
staining (Sigma).  All newly formed cells were identified by BrdU staining (Roche). The number 
of centralized nuclei was determined by counting 5 fields/section at x20 magnification.  A total 
of 5 slides/ animal were assessed using fluorescent microscopy (Carl Zeiss, ApoTome). 
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Capillary density was evaluated by staining with an antibody against von-willebrand factor 
(vWF) (DAKO). The number of capillaries (defined as 1 or 2 endothelial cells spanning the 
vWF-positive vessel circumference) was determined by counting 5 fields/ section at x 20 
magnification. A total of 5 slides/ animal were assessed and the amount of capillaries was 
expressed per no. of myofibers. Double staining for BrdU/ vWF was performed to identify newly 
formed capillaries and counterstained with DAPI to detect nuclei using fluorescent microscopy 
(Carl Zeiss, ApoTome). Tracking of donor GFPpos cells was achieved by staining with anti-GFP 
(Rockland).  GFPpos cells were quantified by counting 5 fields/ section at x20 magnification. A 
total of 5 slides/ animal were assessed and number of GFPpos cells quantified.  To identify 
whether transplanted cells retained their PIC phenotype in vivo, sections were stained against 
PW1 (antibody kindly gifted by D. Sassoon), Pax7 (DSHB) and images of were acquired using a 
confocal microscope (Nikon, A1R). Bi-potent myogenic differentiation was assessed by staining 
for MHC (DSHB) and smooth muscle actin (Sigma) as previously described (15). Macrophages 
were identified by staining with anti-IBA-1 (Wako). IBA-1pos macrophages were quantified by 
imaging 5 fields/ section at x 20 magnification using fluorescent microscopy (Carl Zeiss, 
ApoTome). Staining intensity was subsequently quantified using ImageJ analysis. All secondary 
antibodies were purchased from ThermoFisher.   
 
Gene expression profiling  
To identify growth factors and cytokines expressed by undifferentiated and early myogenic 
differentiated pPICs, gene array analyses were performed (n=3/group). RNA was extracted from 
pPICs that were either maintained in an undifferentiated condition in standard growth media or 
placed in a myogenic permissive environment (DMEM/F12, 2% horse serum) for 24 hours.   
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Total RNA was isolated using the Qiagen RNeasy Mini Kit and reverse transcribed using the 
RT2 first strand kit (Qiagen) according to the manufacturer’s recommendations for the RT2 
Profiler PCR Array. Quantitative RT-PCR was then performed using RT2 SYBR Green (Qiagen) 
and the RT2 Profiler PCR Array (Qiagen), which was custom-designed for the identification of 
porcine growth factors and cytokines of interest. Briefly, samples were denatured for 10 minutes 
at 95°C, cycled 40 times at 95°C for 15 seconds, followed by 40 cycles at the annealing 
temperature of 60°C for 1 minute on a MyIQ thermocycler (BioRad). All reactions were carried 
out in triplicate; data were normalized to five housekeeping genes (ACTB, B2M, GAPDH, 
HPRT1, RPL13A) and analyzed using BioRad IQ software.   
 
Western blotting 
Immunoblots were carried out using protein lysates obtained from undifferentiated pPICs and 
pPICs that had undergone early myogenic differentiation (n=3/group). Approximately, 50 μg of 
protein were separated on gradient (10-15%) SDSpolyacrylamide gels. After electrophoresis, 
proteins were transferred onto nitrocellulose membranes and blocked with 5% dry milk, then 
incubated with antibodies against IGF-1 (Santa Cruz), HGF (Santa Cruz), TGF-β1 (Santa Cruz), 
NRG-1 (Santa Cruz) at dilutions suggested by the manufacturers. GAPDH (Millipore) was used 
as a loading control. Proteins were detected by chemiluminescence using HRP-conjugated 
secondary antibodies (Santa Cruz) and visualized using ECL Plus Western Blotting Detection 
Reagents (Amersham Ltd.) and a Chemidoc imaging system (Bio-Rad Ltd.).   
 
BrdU proliferation assay in vitro  
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pPICs and human myoblasts were plated in 24-well plates at a density of 5 x 103 per well and 
were serum starved for 6 h in 0% serum DMEM/F12 medium. To investigate the effect of pPIC 
conditioned media on proliferation, wells were either supplemented with standard growth media, 
unconditioned media, pPIC conditioned media or heat inactivated conditioned media.  Each well 
was supplemented with BrdU (1ug/ml) every 8 h, fixed after 24 h and BrdU incorporation was 
assessed using the BrdU detection kit (Roche) (n=3/condition).  
In order to investigate the effect of growth factors on pPIC proliferation, wells were serum-
starved for 6h and then switched to basal media (control), or supplemented with IGF-1 
(100ng/ml; Peprotech), HGF (100ng/ml; Peprotech), neuregulin-1 (NRG-1; 100ng/ml; R&D) or 
TGF-β1 (5ng/ml; Peprotech).  Each well was supplemented with BrdU (1ug/ml) every 8h, fixed 
after 24h and BrdU incorporation was assessed using the BrdU detection kit (Roche) 
(n=3/growth factor). Nuclei were counterstained with DAPI. Cells were evaluated using 
fluorescence microscopy (Carl Zeiss, ApoTome). The percentage of BrdU positive cells relative 
to the total number of cells was determined by counting 5 random fields at x20 magnification for 
each dish, and then expressed as fold change over un-supplemented control.  
Myogenic differentiation assay in vitro                                                                                       
To assess the effect of different growth factors in the induction of myogenic differentiation in 
vitro, 1 x 104 pPICs were plated in 24- well plates on gelatin-coated coverslips in basal media 
(control). Individual growth factors (concentrations stated above) were supplemented 
(n=3wells/growth factor). 3 wells acted as controls, with no growth factors added to the medium. 
Cells were fixed after 5 days and myogenic differentiation was quantified by staining for MHC 
(DSHB). Nuclei were counterstained with DAPI. Cells were evaluated using fluorescence (Carl 
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Zeiss, ApoTome), 5 random fields at x20 magnification were quantified for each well and fusion 
index was calculated by counting the number of nuclei inside myotubes per total nuclei. 
Matrigel angiogenesis assay                                                                                                          
To study angiogenesis, 150 μl of Matrigel substrate diluted with DMEM (1:10) was pipetted into 
each well of a 24-well plate and allowed to solidify for 1hr at 37°C. Thereafter, 2x104 HUVECs 
were seeded into each well in either EBM (see details above), unconditioned media (serum-free), 
pPIC conditioned media or heat inactivated conditioned media. Cells were imaged at 24h using a 
light microscope (Olympus). Five fields of view at 20x magnification were imaged for each 
condition. Parameters of angiogenesis (capillary area, number of tubes per field of view, tube 
length and branching points) were analyzed using Wimasis Image Analysis software.  
Cytotoxicity assay in vitro 
Peripheral blood mononuclear cells (PBMCs) were isolated from whole pig blood using density 
gradient centrifugation with Ficoll-Paque (Sigma). Briefly, whole blood was diluted at the ratio 
of 1:1 with PBS and carefully layered over 6 mL of Histopaque solution. Tubes were centrifuged 
at 400g for 30 min at room temperature. PBMCs were then carefully collected from the buffy 
coat layer, washed twice with PBS and frozen at -80 until ready to use.  PBMCs were 
resuscitated and cultured for 3 days in RPMI 1640 GlutaMAX medium (Gibco), 10% FBS and 
1% pen/strep (Gibco). PBMCs were either maintained in media alone or activated with 
phytohemagglutinin (PHA) (Sigma) (5 μg/ml) for 3 days. PICs (passage 6) were plated at 1x105 
per well in a 24 well plate, 1 day before co-culture. PBMCs were harvested and co-cultured with 
PICs in RPMI medium as follows; no PBMCS, 1:10, 1:20 and 1:40. After 4 h of co-culture, 
PBMCs were discarded, PICs were harvested and subsequently labelled with anti-CD45 antibody 
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(BD Biosciences)/Annexin V-PE Apoptosis Detection Kit I (BD Pharmigen) and analysed using 
flow cytometry. 
Statistical analysis                                                                                                                             
Data are reported as Mean ± SD. Significance between 2 groups was determined by paired 
samples T-test and in multiple comparisons by analysis of variance (ANOVA). Holm-Šídák 
method was used to locate the differences. A probability of less than 5% (P < 0.05) was 



























Cardiotoxin-induced injury is a reproducible model of porcine skeletal muscle damage 
In order to determine a robust model to investigate allogeneic pPIC regenerative therapy in vivo, 
two different models of porcine skeletal muscle damage were first evaluated. Freeze/crush and 
cardiotoxin (CTX) injury were assessed as they have been extensively used to model skeletal 
muscle damage in small animals (28).  The freeze/crush injury is a segmental model of trauma, 
selectively affecting muscle fibers and interstitial tissue without disrupting the main innervation 
of the tissue.  The CTX injury, induced using a series of cardiotoxin injections, is a diffuse injury 
model. All animals recovered from the surgical procedure without complications and were fully 
ambulatory within a few hours after surgery with only minor swelling observed at the surgical 
site. Histological assessment of explanted muscle revealed that the freeze/crush injury, as 
expected, was restricted to the superficial layer of muscle adjacent to a deep uninjured region 
(Fig. S1).  CTX-injured muscles showed a diffuse pattern of damage throughout the tissue (Fig. 
S1).  Both injuries resulted in significantly (p<0.05) decreased muscle fiber CSA (CTX-injured 
53% ± 7% per total area; freeze/crush-injured 66% ± 7% per total area), compared to uninjured 
contralateral control muscle (83% ± 4% per total area) (Fig. S1).  Moreover, CTX-injured 
muscle exhibited a significant (p<0.05) reduction in muscle fiber CSA, compared to 
freeze/crush-injured muscle (Fig. S1), showing that CTX injury damaged a greater number of 
myofibers. There was also a significant (p<0.05) increase in the abundance of connective tissue 
in both injury models (Fig. S1).  Both injuries resulted in an overall reduction in muscle fiber 
diameter with CTX injury showing the greatest reduction (37.9 ± 8.5μm), which was statistically 




A decreased myofiber diameter implies the occurrence of small, newly formed, regenerating 
myofibers. Therefore, centralized nuclei, a marker of newly regenerated fibers, were evident in 
both injuries however they were more prevalent in the freeze/crush-injured muscle (27.27 ± 
11.34 per 100 myofibers; p<0.05), compared to CTX-injured muscle (10.8 ± 6.0 per 100 
myofibers) and uninjured control (Fig. S1), suggesting that freeze/crush-injured muscles were 
more advanced in the regeneration process at 14 days post-injury, compared to CTX-injured 
muscles.  Immunohistochemical staining of injured muscle was performed to determine the 
extent of regeneration with respect to early myosin isoforms. Neonatal myosin heavy chain 
(nMHC) staining was observed in both larger fibers and small angular myofibers of CTX and 
freeze/crush-injured muscle at 14 days post-injury (Fig. S1) and in the freeze/crush injury nMHC 
expressing myofibers were restricted to the uppermost superficial layer of the muscle.  The CTX-
injured muscles showed a diffuse pattern of nMHC expression and nMHCpos myofibers were 
more prevalent in CTX-injured muscle (37.2% ± 5.7%) compared to freeze/crush injured muscle 
(25.6% ± 5.3%). nMHCpos fibers were also smaller in CTX-injured muscle (21.7μm ± 4.9μm) 
compared to those identified in the freeze/crush-injured muscle (24.8μm ± 5.3μm), supporting 
our observation that freeze/crush injury regeneration is more advanced at 14 days compared to 
CTX-injury, which induces widespread injury with incomplete regeneration at 14 days post-
injury (Fig. S1).  
These results confirmed that CTX injury is a reproducible and diffuse injury model for testing 
skeletal muscle regeneration in the pig.  However in order to confirm whether 14 days was an 
appropriate time point for studying porcine skeletal muscle regeneration, a subset of animals 
were also sacrificed 21 days post-CTX injury.  Immunohistochemical staining of muscle cross-
sections revealed that at 21 days there was no significant (p<0.05) difference between the muscle 
19 
 
fiber or connective tissue CSA (75% ± 3% muscle fiber per total area), compared to uninjured 
control (82% ± 3% muscle fiber per total area) (Fig. S2). These findings suggest that 21 days 
after CTX injury the muscle has undergone almost complete regeneration.  Therefore, to measure 
whether allogeneic pPIC transplantation could enhance the regeneration of skeletal muscle, CTX 
was selected as the injury model with sacrifice of the pigs at 14 days post-injury. 
 
Transplantation of allogeneic GFPpos pPICs improves skeletal muscle architecture and 
accelerates myofiber regeneration 
pPICs, which have previously been phenotyped and propagated over long term culture 
maintaining phenotypic and genomic stability (16), were transduced with a lentiviral vector 
encoding a GFP reporter. 87.2% of pPICs were GFP-positive as determined by flow cytometry 
(Fig. S3).  GFPpos pPICs (GFPpPICs) were propagated over 9 passages (P3-P12) to generate the 
required number of cells for transplantation (20x106 per animal).  GFPpPICs maintained a PIC 
phenotype after GFP transduction, which was stable up to P12, remaining positive for PW1, 
CD34 and negative for CD45 and Pax7 (Fig. S3). Furthermore, GFPpPICs at P12 were 
comparable in their gene expression profile and bi-potent differentiation potential to unlabelled 
pPICs (Fig. S3). 
 
Initial histological observations indicated that pPIC-treated muscle had significantly improved 
muscle architecture and increased BrdUpos centralized myonuclei, indicative of undergoing 
accelerated regeneration, compared to CTX-PBS treated muscle (Fig. 1a-b).  There was a 
significant (p<0.05) increase in muscle fiber CSA in pPIC-treated muscle (78% ± 5% per total 
area), compared to CTX-PBS (62% ± 2% per total area) (Fig. 1c) and the ratio of muscle 
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fiber:connective tissue CSA of pPIC-treated muscle (78%:22% ± 5% per total area) at 14 days 
was closer to uninjured contralateral control muscle (87%:13% ± 3% per total area)  (Fig. 1c).  
 
Immunohistochemistry revealed a marked increase (p<0.05) in the number of centralized, 
BrdUpos myofiber nuclei, which indicates newly regenerated fibers, in pPIC-treated muscles 
(15% ± 3% /total myofibers), compared to CTX-PBS treated muscles (2% ± 1% /total 
myofibers) (Fig. 1b & d).  The uninjured contralateral control muscle had a very low number of 
BrdUpos nuclei and centralized nuclei, indicating the low turnover of skeletal myofibers in 
uninjured, resting muscle (0.04% ± 0.08%) (Fig. 1b & d). The diameter of the BrdUpos 
regenerating myofibers in pPIC-treated muscles were found to be significantly larger (41.4μm ± 
10μm) than those of CTX- PBS treated muscles (23.8μm ± 7.3μm) 14 days post-injury (Fig. 1e). 
Taken together, these findings support an improved and accelerated regeneration of injured 
skeletal muscle, following transplantation of allogeneic pPICs.  
 
Allogeneic pPICs stimulate neo-angiogenesis when transplanted into injured porcine skeletal 
muscle 
Immunohistochemical staining revealed a significant (p<0.05) increase in capillary density with 
CTX-pPIC treatment, compared to CTX-PBS and uninjured muscle (Fig. 2a-b). Moreover, the 
presence of BrdUpos/vWFpos capillaries in the pPIC-treated muscle confirmed their formation 
post-injury and pPIC transplantation (Fig. 2c). Quantification revealed a significant (p<0.05) 
increase in the number of BrdUpos/vWFpos capillaries in pPIC-treated skeletal muscle (93.94 ± 
2.86 per myofiber), compared to CTX-PBS-treated (55.84 ± 2.86 per myofiber) (Fig. 2d). These 
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findings show that allogeneic pPIC therapy stimulated angiogenesis in the injured skeletal 
muscle.  
 
Allogeneic pPIC transplantation activates endogenous PICs 
To determine whether GFPpPIC transplantation had stimulated the activation of endogenous 
progenitor cells, sections were stained for PW1, Pax7 and GFP. We found a significant (p<0.05) 
increase in the number of endogenous PW1pos/Pax7neg/GFPneg PICs in skeletal muscle that had 
been treated with allogeneic GFPpPICs (7.9% ± 1.9%/total nuclei), compared to CTX-PBS-
treated CTRL (4.6% ± 0.5%/total nuclei) (Fig. 3a-b). We also quantified the number of 
PW1pos/Pax7pos/GFPneg satellite cells, and found that pPIC treatment did not significantly alter 
the number of satellite cells (2.6% ± 0.4%/total nuclei), compared to CTX-PBS treatment (2.4% 
± 0.5%/total nuclei) (Fig. 3c-d). These data show that at 14 days post-injury allogeneic pPIC 
transplantation had a stimulatory effect on the endogenous pPICs population resulting in an 
increase in their number.  
 
Allogeneic GFPpos pPICs are cleared by the host’s immune system 
To determine whether allogeneic GFPpPICs had persisted in the skeletal muscle and directly 
contributed to the regeneration or, as expected, had been cleared by the host’s immune system, 
skeletal muscle cross-sections were co-stained for GFP and laminin.  Only a few GFPpPICs (1 
GFPpos nuclei/1560 counted) persisted within the skeletal muscle 14 days post-injury (Fig. 4a-b). 
Moreover, we found that the very few donor GFPpPICs that had remained, had taken up 
residence within the interstitial spaces and maintained expression of PW1.  No GFPpos nuclei 
were identified underneath the basal lamina in a satellite cell position (Fig. 4a, Figure S4). We 
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found only a rare occurrence of a single GFPpos myofiber (per 1000 myofibers counted) (Fig. 4a-
b).  At 14 days post-injury no GFPpPICs were identified in other tissues (lung, spleen or liver) or 
in the uninjured contralateral control muscle (Fig. S4).  
Muscle sections were stained for the infiltration of cytotoxic T cells, cytotoxic T cells/natural 
killer cells and macrophages expressing CD8a, Granzyme B and IBA-1, respectively (Figure 
S5). CD8apos and Granzyme Bpos cells were significantly upregulated in CTX-pPIC treated 
muscle, compared to CTX-PBS and uninjured muscle (Fig 4c,d). In terms of the innate 
immunity, IBA-1-positive macrophages infiltration was significantly increased in both CTX-PBS 
and CTX-pPIC treated muscle relative to uninjured muscle (Fig. 4e).  
To document that the immune cells (cytotoxic T cells/NK cells) were responsible for clearance 
of pPICs we performed cytotoxicity assays with porcine peripheral blood mononuclear cells 
(PBMCs) in vitro.  Porcine PHA-activated and inactivated PBMCs were co-cultured with pPICs 
at several seeding densities and apoptosis (Annexin V/7-AAD) of pPICs measured by flow 
cytometry. Activated PBMCs induced apoptosis between 70-80% in pPICs (Fig. 4f). Apoptosis 
of pPICs did not occur when inactive PMBCs were co-cultured with pPICs (Fig. 4g).  
Taken together these data suggest that allogeneic pPICs exert their action via a paracrine effect, 
activating endogenous progenitors before being cleared by the host immune system post-injury. 
 
Allogeneic pPICs express an array of pro-regenerative paracrine factors 
To identify the mechanism through which pPICs were able to promote regeneration in skeletal 
muscle, we looked to their secretome.  Porcine PICs were found to express a range of 
cytoprotective/ pro-regenerative growth factors and cytokines (Fig. 5a) similar to that observed 
for stem/progenitor cells, such as mesenchymal stem cells (MSCs) (29) and satellite cells (30).  
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In particular we noted the greatest relative expression (>10,000) was Chemokine (C-C Motif) 
Ligand 2 (CCL2), monocyte chemotactic and activating factor, which is considered to be 
essential for stimulating muscle repair (31, 32) (Fig 5a). TIMP1 and TIMP2, involved in tissue 
remodeling were also highly expressed (>100 relative expression; Fig 5a). Factors which were 
10-100 relative expression included those implicated in the activation, migration, proliferation 
and differentiation of muscle stem/progenitor cells, such as Periostin, Neuregulin 1/2, TGF-βs, 
FGFs, HGF, IGF-1, INHBA, LIF, IL-6 and SCF (33-42) (Fig.5a). Interestingly, GDF-11, which 
has been shown to ameliorate the age-related dysfunction of skeletal muscle by rescuing the 
function of aged muscle stem cells (43), was significantly expressed by pPICs (Fig.5a). Pro-
angiogenic factors including VEGFa, PDGFs and IL-8, capable of stimulating recruitment of 
endothelial cells and initiating vascularization following injury (44-46), were also found to be 
highly expressed (>10) in pPICs (Fig. 5a). 
 
To enrich for a highly paracrine secreting pPIC population, we identified whether pPICs 
expressed differential levels of factors depending on their differentiation status. This was 
necessary because following pPIC transplantation into injured skeletal muscle the 
microenvironment could facilitate pPICs to differentiate into a myogenic precursor-like cell type, 
which could then express differential levels of pro-regenerative factors, compared to its 
undifferentiated counterpart. Therefore, a comparative qRT-PCR analysis was performed 
between undifferentiated pPICs and those which had undergone 24 hours of myogenic 
differentiation in vitro (differentiated pPICs).  Overall, there were distinct differences between 




Volcano plot analysis highlighted factors that were significantly (>2-fold) down- or upregulated 
in differentiated compared to undifferentiated pPICs (Fig. 5c; Table S1). Cytokines and growth 
factors involved in stem cell migration and proliferation, such as HGF (9), were upregulated in 
undifferentiated pPICs. Whereas, a significant upregulation of factors involved in 
stem/progenitor activation and differentiation, such as INHBA, SPP-1, IL-8, BMP4, IGF-1, 
NRG-1 and Periostin, were expressed in differentiated pPICs. (Fig. 5c). We confirmed changes 
in expression at the protein level of undifferentiated compared to differentiated pPICS for a 
selected panel of up- or down-regulated factors, which supported the transcript data (Fig. 5d). 
These data suggest that both undifferentiated and differentiated pPICs could be used to exert a 
pro-regenerative paracrine effect, but differentiated pPICs upregulate expression of a more vast 
array of pro-regenerative factors.   
 
The pPIC secretome promotes a regenerative response in vitro 
We next examined the effect of the pPIC secretome on human myoblast and pPIC proliferation 
and differentiation in vitro.  pPIC conditioned media significantly (p<0.05) increased 
proliferation of pPICs (Fig. 6a) and myoblasts (Fig. 6b), compared to unconditioned media and 
heat-inactivated media where the secreted factors were denatured (Fig. 6a-b).  Next we showed 
that factors that were expressed by pPICs such as, IGF-1, HGF, and NRG-1, when supplemented 
to pPICs in vitro, increased their proliferation (Fig. 6c) and for TGF-β1, increased pPIC 
differentiation (Fig. 6d-e) assessed by quantifying the fusion index of MHCpos cells, compared to 
unsupplemented control.  Moreover, in vitro angiogenesis assays confirmed that secreted factors 
in pPIC conditioned media promoted HUVECs to form endothelial networks, compared to 
unconditioned media and heat inactivated media (Fig. 6f, 6g and Fig. S5). Taken together these 
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data demonstrate that factors secreted by pPICs promote proliferation and differentiation of 
skeletal muscle progenitors, PICs and stimulate angiogenesis in vitro. 
Administration of HGF and IGF-1 improves skeletal muscle regeneration, but not as great 
as pPIC transplantation 
To determine whether cytokines produced by other cell types other than pPICs could contribute 
to the repair, we immunostained the muscle sections for 4 growth factors, HGF, IGF-1, TGFβ1 
and NRG1.  CTX:pPIC transplanted muscle showed increased expression of all factors, 
compared to CTX:PBS and uninjured muscle. Specifically, HGF expression was mainly 
confirmed to the myofibers, IGF-1 and NRG1 expression was confined to the myofibers and 
interstitial cells and TGFβ1 expression was confined to the interstitial cells, following CTX:pPIC 
transplantation (Fig. S7). 
To determine if IGF-1 and HGF could improve regeneration to a similar degree as pPIC 
transplantation, we injected IGF-1 and HGF into CTX injured skeletal muscle, and we also 
administered the growth factors through a UPy hydrogel, as we have done previously in the 
porcine chronic MI model (47).  We found that IGF-1/HGF administration improved muscle 
regeneration, increased the number of BrdUpos myofiber nuclei (8% ± 2%/total myofibers vs. 2% 
± 1%/total myofibers CTX:PBS) and BrdUpos regenerating myofibers were larger (33.28µm ± 
6.3µm vs. 23.8 µm ± 7.3 µm CTX:PBS)  (Fig. 7). However, these effects were not enhanced if 
the growth factors were administered through the UPy hydrogel (BrdUpos myofiber 8 ± 3% /total 
myofibers and BrdUpos regenerating myofibers diameter 35.58µm ± 4.98µm), and more 
importantly the improvements were not as great as transplantation of pPICs (Fig. 1). Therefore, 
pPICs are superior to targeted growth factor administration as they release a plethora of growth 
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factors and cytokines which activate multiple endogenous repair mechanisms, contributing to 
accelerated and effective repair and regeneration in vivo.  
 
Discussion  
The present study documents that in a porcine model of skeletal muscle damage, which is 
applicable to humans, transplantation of allogeneic pPICs persist long enough to elicit a 
paracrine effect by secretion of regenerative cytokines and growth factors. These factors 
stimulate endogenous progenitor cell activation and differentiation, leading to accelerated and 
improved autologous myofiber regeneration and microvessel formation. 
Skeletal muscle while capable of undergoing extensive regeneration exhibits diminished 
regenerative capacity in ageing and disease.  The loss of regenerative capacity is largely thought 
to be due to intrinsic and extrinsic changes that ultimately abrogate resident progenitor cell 
competence (48, 49).  Intrinsic mechanisms include epigenetic changes, telomere attrition, DNA 
damage or mitochondrial dysfunction. Extrinsic changes are associated with alterations of the 
muscle progenitor cell niche, which can be influenced by both systemic circulating factors and 
local changes associated with ageing, disease or metabolic pathways, which can negatively 
impact endogenous progenitor cells. 
To date, most attempts to regenerate skeletal muscle have focused on delivery of culture-
expanded myoblasts (50) or CD133pos cells (51), which have been shown to engraft and generate 
functional satellite cells after xenotransplantation in rodent models, suggesting the potential for 
autologous regenerative applications. Despite advances, the results of clinical trials (52, 53) 
collectively show low engraftment efficiency with prevailing issues associated with immune 
rejection. Over recent years, a large number of reports have shown that transplanted stem cells 
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mediate their beneficial effects via several indirect mechanisms, such as recruitment of 
endogenous progenitor cells, induction of angiogenesis, protection of existing survived cells and 
reduction in fibrosis and inflammation (9, 54). These processes are regulated by a variety of 
small molecules, proteins, mRNAs/miRNAs and paracrine factors produced by the adoptively 
transferred stem cells in the damaged tissue milieu (54-56). This concept has been prevalent for 
many years, where it was shown the infusion of human umbilical cord blood cells can aid in 
stroke recovery due to enhanced angiogenesis, which may have induced neuroblast migration to 
the site of injury (57). Moreover, transplanted macrophages can promote liver repair by 
activating hepatic progenitor cells (58). We have previously documented the protective and 
regenerative effects of allogeneic cardiac stem/progenitor cell (CSC) transplantation or growth 
factor administration in porcine models of MI (9, 12). Cardiac stem/progenitor cells express high 
levels of numerous cytokines, including chemokines (TCA-3, SDF-1, 6Ckine), vascular growth 
factors (VEGF, EPO, bFGF, SCF), survival and activation factors (IGF-1, HGF, PDGF’s), and 
cardiac differentiation factors (Activin A, Dkk-1, TGF-β), which are released at the site of injury, 
activating endogenous repair mechanisms and improving cardiac function (9, 12, 59, 60).  
To our knowledge this is the first study to show allogeneic stem/progenitor cell transplantation 
elicits a paracrine effect by activating endogenous repair processes to improve and accelerate 
muscle regeneration in the pig. To date pre-clinical studies have not addressed the magnitude of 
the regeneration required to target whole skeletal muscle regeneration in the clinic. The best 
published results report regeneration in the region of milligrams of skeletal muscle in small 
mouse animal models, while humans would likely require at least a 3-fold increase in muscle 
mass in comparison (61).  Here, we developed a large animal, pre-clinical skeletal muscle injury 
model, which is easily reproducible and is a useful, clinically applicable model to assess the 
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effects of proof-of-concept regenerative therapies designed to regenerate large volumes of 
muscle.  The animals utilised were juvenile animals, ~2 month old pigs, which were selected due 
to their reduced size and practicability issues.  They also had a functioning immune system 
required to test our theory that transplanted pPICs would be cleared by the host immune system. 
We showed that transplanted pPICs were cleared from the host by 14 days post-transplantation 
and activated PMBCs from the pig killed pPICs in a cytotoxicity assay in vitro. Analysis of the 
immune response in revealed that CTX:pPIC muscle had increased CD8 (adaptive immunity) 
and Granzyme B (innate immunity) cells and both CTX-PBS and CTX-pPIC –treated muscle 
had comparable infiltration of macrophages that were significantly greater than in uninjured 
muscle.  Taken together we propose that the donor pPICs were removed in the early phases of 
regeneration and the increased regenerative response was mediated as a consequence of the 
activated endogenous progenitors. 
Transplantation of allogeneic pPICs were found to stimulate the endogenous repair mechanisms 
of this tissue leading to improved and accelerated skeletal muscle regeneration, with increased 
muscle CSA, an increased number of BrdUpos centralized nuclei and larger regenerating 
myofibers compared to CTX:PBS-treated muscle. In addition to myofiber regeneration following 
muscle trauma, damaged blood vessels lead to tissue hypoxia at the injury site (63) therefore new 
capillary formation after injury is also necessary for functional muscle recovery (64). Secretion 
of angiogenic factors, such as VEGF at the injury site is an important mediator of this process 
and several studies have shown that VEGF improves skeletal muscle repair by promoting 
angiogenesis (65-66). This study identified that following allogeneic pPIC transplantation there 
was a significant increase in new capillary formation, which would have contributed to the 
improvement in muscle regeneration observed.   
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Allogeneic pPIC- treatment was shown to activate and increase the number of endogenous 
PW1pos/Pax7neg PICs, yet a similar increase in number was not found for PW1pos/Pax7pos satellite 
cells. Therefore, pPICs may either have a greater stimulatory effect on the endogenous PICs or, 
more likely, the time point of 14 days is insufficient to accurately measure the effect of pPIC 
transplantation on satellite cell activation. As satellite cells are the main contributor to muscle 
regeneration (62) it is likely that the satellite cells became activated early (days 1-3) and had 
returned to normal, quiescent levels once the regeneration process was almost complete at 14 
days. Moreover, the assessment of satellite cell activation is hampered by lack of markers to 
identify activated satellite cells in the interstitial space (30). Also, the endogenous PICs might 
have maintained an activated state for longer due to their role in vascular repair. However, these 
data suggest the existence of a feedback loop triggered by the transplanted pPICs that activates 
the production of growth and survival factors by the endogenous PICs, which could explain their 
persistence and longer duration of activation over 14 days. The relationship between satellite 
cells and endogenous PICs during the repair and regeneration of skeletal muscle thus warrants 
further investigation.   
We determined if the paracrine effect of pPICs depended on their differentiation status and 
predicted that upon transplantation, the in vivo microenvironment encountered by the pPICs 
during the first 24 hours would promote pPIC differentiation. The secretome of 24hr 
differentiated pPICs showing increased expression of factors such as IGF-1, NRG-1 and TGF-β1 
and periostin, which facilitated proliferation and differentiation of endogenous muscle 
stem/progenitor cells. In vitro assays confirmed that conditioned media containing these secreted 
factors stimulated the proliferation of both pPICs and human myoblasts, and stimulated 
endothelial network formation of HUVECs. Moreover, IGF-1, HGF and NRG-1 when 
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supplemented individually to the culture media stimulated the proliferation of pPICs, while TGF-
β1 was shown to play a role in promoting pPIC myogenic differentiation. Therefore, allogeneic 
pPIC transplantation elicits a paracrine effect on endogenous progenitor cells, increasing and 
accelerating skeletal muscle regeneration. 
Many different stem/progenitor cells (67-73) have been investigated for cellular therapy each 
with their own set of unique advantages and shortcomings.  Given the striated muscle similarities 
between skeletal and cardiac muscle, skeletal-muscle derived myoblasts were the first cell type 
to enter the clinical arena of heart repair (74).  Skeletal muscle-derived progenitors showed 
promise in that they were pro-angiogenic and relatively resistant to hypoxic conditions therefore 
improved functional outcomes upon transplantation (75-76). However, due to issues associated 
with limited expansion in vitro and arrhythmogenic complications in vivo (77) they are widely 
considered unsuitable for cardiac regeneration.  Utilizing PICs as a source of stem/progenitor 
cells for allogeneic cell therapy overcomes several of the limitations encountered with other 
adult muscle progenitor therapies and mesenchymal allogeneic therapies. Indeed, harvesting of 
PICs from an easily accessible source such as skeletal muscle means a simple muscle biopsy 
would be performed, and with an unlimited proliferative capacity in vitro a large number can be 
propagated, maintaining a stable phenotype and genotype over passage number (16). Together 
with a rich secretome of regenerative factors, these properties make PICs an ideal candidate cell 
source for the repair of the heart as well as other tissues.  
 
One of the main limitations associated with the clinical application of stem cell based therapies is 
the time and costs associated with generating the large number of clinical grade cells required for 
treatment.  Therefore, it may be beneficial to assess the effect of different doses of pPICs to 
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ascertain whether fewer cells could stimulate the same effect.  Nevertheless, we envision the 
main advancement of these findings to be in identifying specific factors responsible for eliciting 
accelerated and improved muscle and microvessel regeneration.  This would enable us to 
develop cell-free therapies that match or exceed the level of regeneration reported here, which 
would greatly facilitate clinical application. However, the delivery of HGF and IGF-1 to the 
injured skeletal muscle did not result in equivalent levels of muscle regeneration documented for 
the pPIC transplantation. Therefore, delivery of a multitude of factors/molecules is necessary, at 
different time points after injury, to elicit optimal repair and regeneration of the tissue.   
Another limitation of this study is the unknown effect of transplanting PICs into diseased 
muscle, such as diabetes or muscular dystrophy models, where the harsh environment and 
metabolic elements affect stromal stem cell activity and potency (78).  Moving towards clinical 
application this warrants investigation as we may require a combinatorial approach in order to 
overcome the harsh environments that the transplanted PICs will likely encounter.  Taken 
together, these results provide the proof-of-concept needed to justify further experimental 
development and refinement of this allogeneic cell therapy approach, which ultimately could 
lead to an effective, simple, clinically applicable, and widely available protocol of tissue repair 
and regeneration. 
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Fig. 1.  Transplantation of GFPpos allogeneic, pPICs accelerates skeletal muscle regeneration.    
(a) HVG staining of uninjured CTRL, CTX:PBS and CTX:pPIC-treated muscle showing 
improved skeletal muscle architecture in pPIC-treated muscle, scale bar 100μm. Inset shows 40x 
magnification, scale bar 50μm. (b) Immunohistochemical staining indicates an increase in 
BrdUpos centralized nuclei in CTX:pPIC-treated muscle compared to uninjured:CTRL and 
CTX:PBS-treated muscle, scale bar 50μm. (c) Quantification of the ratio of skeletal muscle to 
connective tissue CSA in uninjured CTRL, CTX:PBS and CTX:pPIC-treated muscle determined 
from five fields of view per muscle, n=5 animals per group.  Data are mean ± SD, *P=0.05 vs. 
uninjured CTRL, **P=0.05 vs. CTX:pPICs. (d) BrdUpos centralized nuclei per total myofibers, 
determined from five fields of view per muscle, n=5 animals per group.  Data are mean ± SD, 
*P=0.05 vs. uninjured CTRL, **P=0.05 vs. CTX:PBS. (e) Average myofiber diameter of 
regenerating (BrdUpos centralized nuclei) myofibers determined from five fields of view per 
muscle, n=5 animals per group.  Data are mean ± SD, *P=0.05 vs. CTX:PBS. 
 
Fig. 2. Allogeneic GFPpos pPICs stimulate neo-angiogenesis following transplantation into 
injured skeletal muscle. (a) Skeletal muscle cross-sections were stained for vWF to evaluate 
capillary density, scale bar 50μm. (b) Number of capillaries per myofiber, determined from five 
fields of view per muscle, n=5 animals per group. Data are mean ± SD, *P=0.05 vs. uninjured, 
**P=0.05 vs. CTX:PBS. (c) Newly formed BrdUpos/vWFpos capillaries were identified 14 days 
post-injury, scale bar 20μm. (d) Percentage of BrdUpos capillaries per total capillaries, 
determined from five fields of view per muscle, n=5 animals per group. Data are mean ± SD, 
*P=0.05 vs. vs. CTX:PBS. 
 
Fig. 3. Allogeneic GFPpos pPICs stimulate endogenous pPIC activation (a) Representative 
image of GFPneg/PW1pos/Pax7neg pPICs resident in CTX:pPIC-treated skeletal muscle 14 days 
post-injury, scale bar 50μm.  (b) Number of GFPneg/PW1pos/Pax7neg pPICs per total nuclei, 
determined from three fields of view per muscle, n=5 animals per group.  Data are mean ± SD, 
*P=0.05 vs. CTX:PBS. (c) GFPneg/PW1pos/Pax7pos satellite cells per total nuclei, determined 
from three fields of view per muscle, n=5 animals per group.  Data are mean ± SD. (d) 
Representative image of PW1pos/Pax7pos satellite cells resident in both CTX:PBS and CTX:pPIC-
treated skeletal muscle 14 days post-injury, scale bar 50μm. 
 
Fig. 4. Allogeneic GFPpos pPICs are cleared by the host immune system (a) 
Immunohistochemistry identified a small number of donor GFPpos pPICs at 14 days post-
transplantation, scale bar 100μm.  GFPpos cells were found as nuclei within the interstitial spaces 
between the muscle fibers (bottom inset) and a rare GFPpos muscle fiber was also identified (top 
inset). (b) Quantification of GFPpos cells to total number of nuclei or myofibers in paraffin 
embedded skeletal muscle cross-sections, n=5.  Data are mean ± SD, *P=0.05 vs. CTX:PBS.  (c) 
Quantification of CD8pos cells per total nuclei (%) determined from five fields of view per group. 
Data are mean ± SD, *P=0.05 vs. uninjured muscle, **P=0.05 vs. CTX:PBS. (d) Quantification 
of Granzyme Bpos cells per total nuclei (%) determined from five fields of view per group. Data 
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are mean ± SD, *P=0.05 vs. uninjured muscle, **P=0.05 vs. CTX:PBS. (e) Quantification of 
IBA-1pos cells per total nuclei (%) determined from five fields of view per group. Data are mean 
± SD. Porcine PICs were co-cultured with either (f) PHA-activated porcine PBMCs or (g) 
inactivated porcine PBMCs at different ratios and analysed for apoptosis using AnnexinV/7-
AAD staining and flow cytometry. Early apoptosis of CD45neg PICs is represented by AnnexinV 
expression, whereas late apoptosis is represented by double positive AnnexinV/7-AAD staining, 
determined from duplicate wells per group.  Data are mean ± SD, *P=0.05 vs. pPICs only. 
 
Fig. 5. Allogeneic pPICs express an array of pro-regenerative paracrine factors. (a) 
Expression profile of pPICs arrayed by qRT-PCR, relative expression to average expression of 
five housekeeping genes ACTB, B2M, GAPDH, HPRT1, RPL13A. Data are mean ± SD, n=3. 
(b) Hierarchical clustering of differentially regulated pPIC transcripts. The colors in ascending 
order from green to red represent the magnitude of gene expression for the measured average 
difference values.  The tree on the left of the clustergram indicates the pairwise similarity 
relationships between the clustered expression patterns, n=3 for both undifferentiated and 
differentiated pPICs (24 hours in differentiation media). (c) Genes that were differentially 
regulated by at least two fold were selected by a t-test, p<0.01 and are illustrated in a volcano 
plot. Red indicates those genes that were significantly upregulated, black represents genes whose 
expression levels did not significantly change, while green indicates genes that were significantly 
downregulated in differentiated pPICs compared to undifferentiated pPICs, n=3. (d) Western 
blots confirmed that pPIC exposure to a myogenic permissive environment led to an increase in 
IGF-1, TGF-β1, NRG-1 and a decrease in HGF protein expression, n=3. 
 
Fig. 6. The pPIC secretome promotes a regenerative response in vitro (a) Quantification of 
pPIC BrdU 24h proliferation assay in standard growth media (GM), 24h pPIC conditioned media 
(CM), unconditioned media (UM), or heat inactivated conditioned media (ICM). Total BrdUpos 
cells per total nuclei, determined from five fields of view per group. Data are mean ± SD, 
*P=0.05 vs. all conditions. (b) Quantification of human myoblasts BrdU 24h proliferation assay 
in GM, CM, UM or ICM. Total BrdUpos cells per total nuclei, determined from five fields of 
view per group. Data are mean ± SD, *P=0.05 vs. UM and ICM. (c) Quantification of BrdU 24h 
proliferation assay in media supplemented with IGF-1, HGF, TGF-β1 or NRG-1 compared to 
control. Total BrdUpos cells per total nuclei, determined from five fields of view per group. Data 
are mean ± SD, *P=0.05 vs. control and TGF-β1. (d) Representative micrographs of pPIC 
immunocytochemical staining for MHC after 5 days of myogenic differentiation in the presence 
of IGF-1, HGF, NRG-1 or TGF-β1 compared to control. (e) Quantification of pPIC fusion index 
after 5 days of myogenic differentiation in the presence of IGF-1, HGF, TGF-β1 or NRG-1 
compared to control. Data are mean ± SD, *P=0.05 vs. control for >3 nuclei. (f-g) Endothelial 
network formation quantified as capillary area (f) and total length of capillaries (g), after 
HUVECs were exposed to endothelial growth medium (GM), pPIC conditioned media (CM), 
unconditioned medium (UM) and heat-inactivated conditioned media (ICM). Data are mean ± 
SD, *P=0.05 vs. ICM and GM.  
 
Fig. 7.  Administration of IGF-1/HGF and UPy IGF-1/HGF stimulates moderate skeletal 
muscle regeneration.    (a) HVG staining of uninjured, CTX:IGF-1/HGF and CTX:UPy IGF-
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1/HGF-treated muscle, scale bar 100μm. (b) Immunohistochemical staining shows a number of 
BrdUpos centralized nuclei in both CTX:IGF-1/HGF and CTX:UPy IGF-1/HGF-treated muscle 
compared to uninjured muscle, scale bar 50μm. (c) Quantification of the ratio of skeletal muscle 
to connective tissue CSA in uninjured, CTX:IGF-1/HGF and CTX:UPy IGF-1/HGF-treated 
muscle determined from five fields of view per muscle, n=5 animals per group.  Data are mean ± 
SD, *P=0.05 vs. uninjured CTRL. (d) BrdUpos centralized nuclei per total myofibers, determined 
from five fields of view per muscle, n=5 animals per group.  Data are mean ± SD, *P=0.05 vs. 
uninjured CTRL. (e) Average myofiber diameter of regenerating (BrdUpos centralized nuclei) 
myofibers determined from five fields of view per muscle, n=5 animals per group.  Data are 
mean ± SD, *P=0.05 vs. uninjured CTRL. 
 
 
